Filter Results
Filter Results
Media Advisory (18) Partnerships (18) General (16) New Technologies (9)
2026 (9) 2025 (5) 2024 (3) 2023 (2) 2022 (8) 2021 (5) 2020 (3) 2019 (4) 2018 (3) 2017 (1) 2016 (2)
English (45)
EnglishX
Reset Filters
   Loading...
Showing 1‐10 of 45
Media Advisory
02 Jul 2026
Lonza Acquires Rights to Nona Biosciences’ TfR1 Blood-Brain Barrier Technology and Expands Strategic Collaboration
Lonza acquires rights to Nona Biosciences’ blood-brain barrier (BBB) technology, leveraging the brain's iron gateway through a receptor, TfR1, to open new routes for...
News Release
30 Jun 2026
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing
Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market Investment supports Lonza’s position in the...
Media Advisory
22 Jun 2026
Lonza and InduPro Announce Licensing Agreement to Advance Next-Generation ADC Therapeutics
InduPro to license Lonza’s linker payload technologies and bioconjugation platforms, as InduPro expands its novel ADC therapeutics  Strategic agreement expands access...
Media Advisory
15 Jun 2026
Lonza Grants Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza’s site-specific...
Media Advisory
09 Jun 2026
AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza
New agreement provides AmMax with access to Lonza’s GlycoConnect®, HydraSpace®, and SYNtecan™ linker-payload technologies Agreement to target development of novel...
Media Advisory
04 Jun 2026
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies
Multi-target agreement positions Stipple Bio to advance next-generation ADC therapies using Lonza’s clinically validated ADC platform Stipple Bio’s Pointillist Platform...
Media Advisory
07 May 2026
Bristol Myers Squibb Licenses Antibody-Drug Conjugate Technology from Lonza
Agreement grants Bristol Myers Squibb (BMS) access to the SYNtecan™ linker-payload platform, along with GlycoConnect® and HydraSpace® technologies Basel, Switzerland, and...
Media Advisory
31 Mar 2026
Swiss Rockets Collaborates with Lonza to Advance Torqur’s Oncology Drug Candidate Bimiralisib into Late-Stage Clinical Development
Lonza collaborates with a biotech innovator to advance a promising oncology drug candidate, bimiralisib cGMP manufacturing to be provided at Lonza’s Highly Potent Active...
Media Advisory
19 Feb 2026
Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation and Development
Lonza strengthens its integrated Advanced Synthesis offering with industry-leading early-phase bioconjugates development capabilities and payload and linker technologies The...
Media Advisory
07 Jul 2025
Lonza Launches Next Generation 4D-Nucleofector® LV Unit PRO for Improved Electroporation in GMP Manufacturing
Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing New system includes optimized cartridge design for improved...
1 2 3 4 ... 5 >